Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of NNC0480-0389 in Combination With Semaglutide s.c
Latest Information Update: 25 Mar 2022
Price :
$35 *
At a glance
- Drugs NNC0480-0389 (Primary) ; Semaglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Novo Nordisk
- 23 Mar 2022 Status changed from active, no longer recruiting to completed.
- 26 Nov 2021 Planned End Date changed from 24 Dec 2021 to 18 Mar 2022.
- 26 Nov 2021 Status changed from recruiting to active, no longer recruiting.